Loading
Skin Diseases and Diabetes · Review
Frontiers in Medicine · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review consolidates evidence that psoriasis, particularly moderate-to-severe disease, is associated with higher prevalence and incidence of type 2 diabetes, and identifies shared inflammatory and metabolic pathways that may explain bidirectional disease relationships. The review concludes that recognition of psoriasis as a systemic inflammatory disease should support earlier screening, cardiovascular risk assessment, and individualized multidisciplinary treatment, though current interventional evidence remains limited and heterogeneous.
Narrative review. Patients with psoriasis, particularly those with moderate-to-severe or longstanding disease; comparison to general population.
Epidemiologic studies consistently show patients with psoriasis, especially those with moderate-to-severe or longstanding disease, have higher prevalence and incidence of T2DM than general population Shared pathogenic pathways include chronic systemic inflammation, dysregulated adipokines, endothelial dysfunction, oxidative stress, and overlapping genetic susceptibility Some antidiabetic agents and biologic therapies may influence both metabolic and dermatologic outcomes, although current interventional evidence remains limited and heterogeneous
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing psoriasis should recognize the systemic nature of the disease and screen for type 2 diabetes and metabolic dysfunction, particularly in patients with moderate-to-severe psoriasis. This may support earlier risk stratification, cardiovascular assessment, and more individualized treatment selection, though specific therapeutic recommendations await stronger interventional evidence.
A narrative review synthesizing epidemiologic evidence and mechanistic pathways to support clinical recognition of psoriasis–T2DM comorbidity and inform screening and treatment strategies, without reporting original trial data.
As stated by the source record.
Clinicians managing psoriasis should recognize the systemic nature of the disease and screen for type 2 diabetes and metabolic dysfunction, particularly in patients with moderate-to-severe psoriasis. This may support earlier risk stratification, cardiovascular assessment, and more individualized treatment selection, though specific therapeutic recommendations await stronger interventional evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Psoriasis is a chronic immune-mediated inflammatory disorder increasingly recognized as a systemic disease rather than an isolated cutaneous condition. In addition to its dermatologic burden, psoriasis is associated with multiple metabolic comorbidities, among which type 2 diabetes mellitus (T2DM) is particularly important because of its prevalence, long-term complications, and potential bidirectional relationship with psoriatic inflammation. Epidemiologic studies consistently suggest that patients with psoriasis, especially those with moderate-to-severe or longstanding disease, have a higher prevalence and incidence of T2DM than the general population. Conversely, metabolic dysfunction, particularly insulin resistance and obesity-related inflammation, may contribute to psoriasis onset and severity. Shared pathogenic pathways include chronic systemic inflammation, dysregulated adipokines, endothelial dysfunction, oxidative stress, and overlapping genetic susceptibility. These mechanistic links have important clinical implications for screening, cardiovascular risk assessment, and therapeutic decision-making. Emerging evidence also suggests that some antidiabetic agents and biologic therapies may influence both metabolic and dermatologic outcomes, although current interventional evidence remains limited and heterogeneous. This narrative review summarizes the epidemiologic evidence supporting the psoriasis–T2DM association, examines shared inflammatory and metabolic mechanisms, and discusses the clinical and therapeutic implications of this comorbidity. Recognizing psoriasis as a systemic inflammatory disease with substantial metabolic consequences may support earlier risk stratification, multidisciplinary care, and more individualized treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.